ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 104 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $219,274 | -39.4% | 45,682 | -5.2% | 0.00% | – |
| Q2 2023 | $362,035 | +95.0% | 48,207 | +17.4% | 0.00% | – |
| Q1 2023 | $185,659 | -36.5% | 41,075 | +58.5% | 0.00% | – |
| Q4 2022 | $292,152 | +21.2% | 25,923 | +2.8% | 0.00% | – |
| Q3 2022 | $241,000 | -13.3% | 25,223 | -26.6% | 0.00% | – |
| Q2 2022 | $278,000 | -51.1% | 34,386 | +346.0% | 0.00% | -100.0% |
| Q3 2021 | $569,000 | -77.3% | 7,710 | -83.2% | 0.00% | -50.0% |
| Q2 2021 | $2,505,000 | -35.0% | 45,819 | -12.3% | 0.00% | -50.0% |
| Q1 2021 | $3,854,000 | +554.3% | 52,258 | +664.6% | 0.00% | +300.0% |
| Q4 2020 | $589,000 | – | 6,835 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |